From: CXC chemokine superfamily induced by Interferon-γ in asthma: a cross-sectional observational study
Asthma patients | Healthy subjects | P value* | |
---|---|---|---|
Subjects, n (%) | 39 | 12 | |
Age, y | 55 (20–72) | 47 (30–57) | 0.02 |
Male/female, n (Male, %) | 16 (41)/23 | 4 (33)/9 | 0.05 |
BMI (kg/m2) | 22.5 (3.8) | 22.2 (3.1) | N.S. |
Duration of asthma (y) | 6.5 (2–16.5) | N. A. | N. A. |
Ex-smokers, n (%) | 14 (36) | 0 (0) | 0.02 |
Medication | |||
ICS dose (μg/day) | 995 (400–1300) | N. A. | N. A. |
Long acting β2-agonist, n (%) | 27 (69) | N. A. | N. A. |
Leukotriene receptor antagonist, n (%) | 27 (69) | N. A. | N. A. |
Oral corticosteroids, n (%) | 8 (21) | N. A. | N. A. |
Atopy, n (%) | 25 (64) | 5 (42) | N.S. |
Asthma control and health care use, past year | |||
β-agonist use/day | 0.00 (0.00–0.03) | N. A. | N. A. |
Oral corticosteroid bursts | 1.0 (0.0–2.0) | N. A. | N. A. |
FEV1, L/min | 2.0 (0.4) | 3.2 (0.8) | <0.0001 |
FEV1, % predicted | 80.4 (20.3) | 105.5 (14.6) | <0.0001 |
FeNO, ppb | 29.5 (14.0–45.5) | N.D. | N. A. |
Cell population in sputum | |||
% Squamous | 16.7 (7.6–25.2) | 32.9 (25.1–42.4) | 0.03 |
% Macrophage | 26.0 (19.0–43.1) | 37.5 (27.6–4 3.2) | N. S. |
% Lymphocyte | 7.3 (4.6–11.9) | 7.5 (3.7–13.4) | N. S. |
% Neutrophil | 29.9 (24.1–51.2) | 21.6 (18.6–24.1) | N. S. |
% Eosinophil | 6.4 (1.6–11.4) | 0.5 (0.0–2.0) | <0.0001 |
% Eosinophil | 38.3 (29.8–63.1) | 23.9 (18.6–24.8) | 0.002 |
+ % Neutrophil | |||
CXC chemokine in sputum | |||
IP-10 (pg/mL) | 60.1 (31.2–306.7) | 31.2 (0.0) | 0.01 |
Mig (pg/mL) | 989.5 (62.5–2698.2) | 62.5 (0.0) | <0.0001 |
I-TAC (pg/mL) | 7.8 (7.8–24.3) | 7.8 (0.0) | N. S. |
IL-8 ( Log, pg/mL) | 3120.3 (3.5, 1442.9 - 9115.1) | 1356.6 (3.0, 522.6 - 2550.4) | 0.01 |